$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
The correct way to take Sotorasibu (AMG 510) and the best treatment planning suggestions
2026-02-01 22:25:32
Check Details
Detailed information on the price and purchasing channels of the Laos imitation Krazati
2026-02-01 22:25:32
Check Details
Contraindications of Pimitespib and instructions for those who are not suitable for use
2026-02-01 22:25:32
Check Details
Afatinib (Gitarel) efficacy, side effects and safe use guidance
2026-02-01 22:25:32
Check Details
The side effects and hazards of DaliRax (Keweike) and how to deal with safe medication
2026-02-01 22:25:32
Check Details
The difference in efficacy and side effects between Lynparza and Niraparib
2026-02-01 22:25:32
Check Details
Venetoclax/Venetoclax (Vekela) 28-day azacitidine 7-day combination therapy regimen
2026-02-01 22:25:32
Check Details
Suggestions on the usage, dosage and dosage adjustment of Asnib/Asiminib
2026-02-01 22:25:32
Check Details
Clinical effects and patient evaluations of ritexitinib (Lefenox) in the treatment of hair loss
2026-02-01 22:25:32
Check Details
Analysis of the molecular targets and mechanism of action of sparsentan
2026-02-01 22:25:32
Check Details
Is Ixazomib an imported drug or a domestically produced drug and explanation of purchase channels
2026-02-01 22:25:32
Check Details
Analysis of how long a course of treatment with Rubitidine/Rubicatin (Zanbiga) lasts
2026-02-01 22:25:32
Check Details
1
2
...
2193
2194
2195
2196
2197
2198
2199
...
10227
10228
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
2
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
7
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
8
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
9
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
10
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
11
Anagrelide vs. Hydroxyurea in Essential Thrombocythemia: Efficacy Profiles and Clinical Positioning
12
SCEMBLIX (Asciminib) Side Effect Management & Special Population Guide